97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01061996
(ClinicalTrials.gov)
July 20072/2/2010Basiliximab Maintenance in Ulcerative ColitisAn Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative ColitisUlcerative ColitisDrug: BasiliximabCerimon PharmaceuticalsNULLTerminated18 Years75 YearsBoth88Phase 2United Kingdom
2EUCTR2006-004303-19-BE
(EUCTR)
08/06/200707/02/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Czech Republic;United Kingdom;Belgium
3EUCTR2006-006319-54-BE
(EUCTR)
24/05/200708/02/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135United Kingdom;Belgium
4EUCTR2006-006319-54-CZ
(EUCTR)
14/05/200720/02/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Belgium;United Kingdom
5EUCTR2006-004303-19-CZ
(EUCTR)
09/05/200720/02/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
181United Kingdom;Czech Republic;Belgium
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-006319-54-SK
(EUCTR)
07/05/200708/03/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Slovakia;Belgium;United Kingdom
7EUCTR2006-004303-19-SK
(EUCTR)
04/05/200708/03/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
181Phase 2Czech Republic;Slovakia;Belgium;United Kingdom
8EUCTR2006-006319-54-GB
(EUCTR)
25/04/200707/12/2006An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Cerimon Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
135 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noCzech Republic;Slovakia;Belgium;United Kingdom
9EUCTR2006-004303-19-GB
(EUCTR)
25/04/200706/12/2006A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Slovakia;Belgium;United Kingdom
10NCT00430898
(ClinicalTrials.gov)
January 200731/1/2007Basiliximab in Moderate to Severe Ulcerative ColitisA Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, With Concomitant Corticosteroids, in Steroid-Refractory Ulcerative ColitisUlcerative ColitisDrug: BasiliximabCerimon PharmaceuticalsNULLCompleted18 Years75 YearsBoth181Phase 2United States;Belgium;Czech Republic;India;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom